# Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

> **NCT00832221** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 10 (estimated)

## Conditions studied

- Depression

## Interventions

- **DRUG:** SEROQUEL XR (quetiapine)
- **DRUG:** SEROQUEL IR (quetiapine)
- **DRUG:** radioligand [11C]raclopride

## Key facts

- **NCT ID:** NCT00832221
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** —
- **Final completion:** 2009-09
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2009-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832221, "Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00832221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*